Scarica l'app Stockscreener
24.29
2.62%
0.62
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$23.67
Aprire:
$23.74
Volume 24 ore:
58.90M
Relative Volume:
1.54
Capitalizzazione di mercato:
$138.44B
Reddito:
$63.32B
Utile/perdita netta:
$7.52B
Rapporto P/E:
18.62
EPS:
1.3043
Flusso di cassa netto:
$9.48B
1 W Prestazione:
-3.65%
1M Prestazione:
-6.03%
6M Prestazione:
-3.19%
1 anno Prestazione:
+0.21%
Intervallo 1D:
$23.74
$24.35
Intervallo di 1 settimana:
$23.62
$25.30
Portata 52W:
$23.11
$28.75
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.29 | 138.44B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,208.12 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
254.66 | 613.02B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
253.35 | 447.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
128.66 | 317.77B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.41 | 296.54B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Aggiornamento | Argus | Hold → Buy |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Underperform |
| 2026-02-20 | Iniziato | Barclays | Underweight |
| 2026-02-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-02 | Ripresa | Citigroup | Neutral |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
A CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock? - The Motley Fool
Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now - Yahoo Finance
Is Pfizer (NYSE:PFE) Building A Stronger Cancer Portfolio? - Kalkine Media
Here's How Many Shares of Pfizer You Must Own to Get $5,000 in Yearly Dividends - Yahoo Finance
Pfizer (PFE) Wins EU Approval For Keytruda And Padcev In Bladder Cancer - simplywall.st
Pfizer Beats Ex-Worker's Whistleblower Retaliation Suit - Law360
Prevnar 20 from Pfizer Inc.broader pneumococcal cover in one syringe - Ad-hoc-news.de
Pfizer Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Price to earnings forward of Pfizer Inc. – BCS:PFECL - TradingView
Why Did Pfizer (NYSE:PFE) Gain Attention After FDA Approval? - Kalkine Media
Pfizer: Why Being Bullish Makes Sense Despite The Patent Cliff (NYSE:PFE) - Seeking Alpha
Nike Names Pfizer’s Denton as Next CFO - WSJ
Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer? - 24/7 Wall St.
Vitiligo Market to Witness Transformational Growth Opportunities by 2034 – DelveInsight | Pfizer, Clinuvel, Inc., Clinuvel Pharma, Bioniz Therapeutics, TAGCyx Biotech - Barchart.com
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Dividend Roundup: Pfizer, AT&T, Comcast, Sysco, and more - Seeking Alpha
Pfizer (PFE) Wins New IBRANCE Use As Lung Cancer Trial Tests Its Pipeline - simplywall.st
Pfizer reaffirmed 2026 guidance after CFO exit, shares trade near recent lows - Ad-hoc-news.de
Price to sales forward of Pfizer, Inc. – NYSE:PFE - TradingView
Pfizer Inc Shs Unsponsored Brazilian Depository Receipts Repr 0.25 Sh Actuals & Estimates (BMFBOVESPA:PFIZ34) - TradingView
Pfizer stock under pressure near yearly lows despite launch of new obesity study programs - Traders Union
Price to earnings forward of Pfizer Inc. – TRADEGATE:PFE - TradingView
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026? - The Motley Fool
Pfizer Inc. Actuals & Estimates (BVC:PFE) - TradingView
Pfizer Inc. stock underperforms Thursday when compared to competitors - MarketWatch
PFE Stock Quote Price and Forecast - CNN
Antibody-Drug Conjugates: Not Quite Worked Out Yet (PFE) - Seeking Alpha
Enterprise value to revenue forward of Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs – BCBA:PFE.B - TradingView
FDA expands Pfizer's Ibrance label for frontline maintenance in advanced breast cancer - MSN
Price to earnings forward of Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs – BCBA:PFE.B - TradingView
Pfizer’s US Paxlovid patent fight turns on a single error - Life Sciences Intellectual Property Review
Nike Joins Alphabet, Walmart in Hiring a CFO From the Outside - Bloomberg
FDA Expands Pfizer's Ibrance Label For Frontline Maintenance In Advanced Breast Cancer - Benzinga
Enterprise value to EBITDA forward of Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs – BCBA:PFE.B - TradingView
Pfizer Declares Third-Quarter 2026 Dividend - BioSpace
ANTITRUST—D. Conn.: Pfizer off the... - VitalLaw.com
Pfizer (PFE) Is Down 7.3% After Mixed Oncology Updates Reshape Its Long-Term Pipeline Narrative - Yahoo Finance
PATENT—Fed. Cir.: Pfizer Inc. prevails in coronavirus-treatment patent dispute with biotechnology company - VitalLaw.com
Pfizer Ducks Generic Drug Claims From State AGs - Law360
Nike Hires Pfizer’s Denton to Take Over for Departing CFO - The Business of Fashion
Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Nike lands Pfizer CFO with $7.3M ‘new hire’ cash award - CFO Dive
Pfizer declares $0.43 quarterly dividend for third quarter By Investing.com - Investing.com Canada
Pfizer Keeps Quarterly Dividend at $0.43 per Share, Payable Sept. 1, to Shareholders of Record July 24 - marketscreener.com
Pfizer Inc. Declares Quarterly Dividend for Third-Quarter of 2026, Payable on September 1, 2026 - marketscreener.com
Pfizer (PFE) Reaffirms FY 2026 Outlook Amid Leadership Change - Insider Monkey
Pfizer Inc. (PFE) Stock: FDA Clears IBRANCE for HER2+ Breast Cancer - parameter.io
Pfizer Dismissed From US States' Lawsuit on Generic Drug Price Fixing - marketscreener.com
Pfizer Inc Stock (PFE) Moved Down by 3.16% on Jun 24: A Full Analysis - TradingKey
FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance - Business Wire
Pfizer Freed From US States’ Drug Price-Fixing Conspiracy Claims - Bloomberg Law News
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):